Abstract
Biologic drugs targeting the IL-23/IL-17 axis have transformed outcomes for people living with psoriasis, allowing most patients to achieve skin clearance. Despite the potential to reveal fundamental regulators of skin homeostasis, the early mechanisms of action of these drugs remain poorly understood. Here, we performed longitudinal single-cell RNA sequencing in individuals with psoriasis who had been successfully treated with IL-23 inhibitor therapy. By profiling skin at baseline, day 3 and day 14 of treatment, we demonstrated that IL-23 blockade causes marked gene expression shifts, with fibroblast and myeloid populations displaying the most extensive changes at day 3. We identified a transient WNT5A+/IL24+ fibroblast state, which was only detectable in lesional skin. The study of ligand-receptor interactions revealed that pro-inflammatory signals stemming from these WNT5A+/IL24+ fibroblasts upregulated multiple genes in differentiated keratinocytes. Importantly, the abundance of WNT5A+/IL24+ fibroblasts was significantly reduced after treatment. This observation was validated in-silico, by deconvolution of multiple transcriptomic datasets, and experimentally, by RNA in situ hybridization of additional skin samples. These findings demonstrate that the evolution of inflammatory fibroblast states is a key feature of resolving psoriasis skin.
Competing Interest Statement
SV is a Boehringer-Ingelheim employee. JNB has attended advisory boards and/or spoken at sponsored symposia and/or received research funding from: AbbVie, Almirall, Amgen, Boehringer-Ingelheim, Bristol Myers Squibb, Celgene, Janssen, Leo, Lilly, Novartis, Samsung, Sun Pharma. CHS reports departmental research funding as investigator in EU-IMI consortia involving multiple industry partners (see biomap-imi.eu and hippocrates-imi.eu for details). FC has received grant support and consultancy fees from Boehringer Ingelheim. SKM reports departmental income from Abbvie, Almirall, Eli Lilly, Leo, Novartis, Sanofi, UCB, outside the submitted work.
Funding Statement
This research was supported by the National Institute for Health and Care Research (NIHR) Biomedical Research Centre based at Guys and St Thomas NHS Foundation Trust and Kings College London (guysbrc-2012-1). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. This work was funded by the Psoriasis Association (PhD studentship ST2/21 RE18411 supporting LF and Grant BSTOP50/5 to CHS) and the Wellcome Trust (grant 096540/Z/11/Z). DMc was supported by the Medical Research Council (grant MR/R015643/1) and Kings College London as a member of the MRC Doctoral Training Partnership in Biomedical Sciences. SKM is funded by a NIHR Advanced Fellowship (NIHR302258). CHS is supported by a NIHR Senior Investigator Award.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The South East London REC 2 Ethics Committee, London, United Kingdom gave ethical approval for this work (REC reference 11/H0802/7)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
